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Abstract
Objective. Liver X receptors (LXRs) have been characterized as regulators of macrophage inflammatory
pathways. Synthetic LXR agonists inhibit the macrophage response to bacterial pathogens and antagonize
the induction of a number of pro-inflammatory genes. The aim of this study was to investigate the pre-
ventive effects of synthetic LXR agonist, GW3965, treatment on the evolution of arthritis and inflammatory
response in a murine CIA model.
Methods. Intradermal injection of bovine type II CIA in DBA/1 mice. Along with the induction of CIA, mice
were treated with oral GW3965 (0.1, 0.3 or 1.0 mg/kg/day) or vehicle from Day 1 to Day 40. Clinical
assessment for arthritis scores and histopathological assessment of joint sections were performed. The
expression of inflammatory mediators was evaluated by immunohistochemical staining. Serum
pro-inflammatory cytokine levels were determined using ELISA.
Results. The CIA incidence was 100% on Day 27 and the severity progressed until Day 35 with histo-
logical features of cartilage erosion in vehicle-treated mice. GW3965 treatment significantly reduced the
arthritis incidence and attenuated the clinical and histological severity, compared with vehicle-treated
mice. GW3965 treatment also significantly reduced inflammatory mediator production in joint sections
and serum pro-inflammatory cytokine levels in a dose-dependent manner.
Conclusions. These results indicate that activation of LXRs suppresses the onset of CIA and reduces
inflammation and joint destruction in CIA mice. The data could suggest that LXR treatment is an effective
prophylactic approach to suppress the evolution of synovitis and resultant joint destruction observed
in RA.
Key words: Rheumatoid arthritis, Liver X receptors, GW3965, Collagen-induced arthritis.
Introduction
RA is an autoimmune disease characterized by chronic
inflammation and cartilage and bone destruction in the
joints. The inflammation of RA results from the production
of prostaglandins, pro-inflammatory cytokines and nitric
oxide. In particular, in the pathogenesis of rheumatoid
synovitis and synovial tissue, macrophages produce a
number of inflammatory mediators and interact with
other cells or extracellular matrix macromolecules.
In addition, macrophages are involved in the oxidative
and nitrosative damage of the joints and their products
mediate synovial angiogenesis. Macrophage-derived
cytokines, such as TNF-a and IL-1b, which are abundant
in synovial tissues and fluid from RA patients, are mito-
gens for synovial fibroblasts and osteoclasts. These
cytokines, acting in both autocrine and paracrine fashions
within the joint space, mediate long-term cartilage degra-
dation and bone erosion [1–6].
Macrophages play essential roles in immunity and lipid
homoeostasis. They function to scavenge pathogens and
apoptotic cells, and it is generally considered that sus-
tained activation of these responses may precipitate
pathological states. Macrophages use the nuclear-recep-
tor superfamily, such as peroxisome proliferator-activated
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receptors and liver X receptors (LXRs). The nuclear
receptor superfamily has diverse and important roles in
regulating reproductive, homeostatic, inflammatory,
immune and metabolic processes [7–10]. Previous studies
have outlined the importance of LXRs (LXR-a, encoded by
the gene Nr1h3, and LXR-b, encoded by the gene Nr1h2) in
the macrophage cholesterol efflux pathway. LXRs are
‘cholesterol sensors’ that regulate the expression of
genes involved in lipid metabolism in response to specific
oxysterol ligands [11]. In macrophages, oxysterols may be
derived from internalized oxidatively modified low density
lipoproteins (oxLDL) or generated intracellularly from mod-
ified cholesterol [12, 13]. LXR activation in macrophages
induces expression of several genes involved in lipid
metabolism and reverse cholesterol transport, exerting
an atheroprotective effect. In addition, LXRs have more
recently been characterized as macrophage inflammatory
pathway regulators. Mice lacking LXRs show an
exaggerated response to lipopolysaccharide. Synthetic
LXR agonists inhibit the macrophage-response to
bacterial pathogens and down-regulate a number
of pro-inflammatory genes. These include IL-1b, IL-6,
MMP-9, inducible nitric oxide synthase (iNOS),
cyclo-oxygenase 2 (COX2), adhesion molecules and che-
mokines [14–16]. Some of these genes are preferentially
sensitive to LXRs, indicating LXR-specific effects on
inflammatory responses. LXR ligands repressed inflamma-
tory gene expression in macrophages derived from wild-
type, Lxra/ and Lxrb/ mice, but could not do so in cells
from Lxrab/ mice, indicating that both LXR isoforms
possess anti-inflammatory properties [17, 18]. The precise
molecular mechanisms responsible for inhibiting inflam-
matory response genes by LXRs remain to be established,
but are at least in part linked to nuclear factor-kB (NF-kB)
inhibition [16, 17, 19].
Inflammatory rheumatic diseases, including RA, are
significant risk factors in atherosclerosis and coronary
heart disease [20, 21]. Furthermore, patients with active
RA show altered lipid metabolism, which can be reversed
by intensive anti-rheumatic treatment [22], and some of
the shared inflammatory mechanisms responsible for
rheumatoid synovitis are thought to be directly involved
in producing atherosclerotic lesions [23, 24]. These obser-
vations suggest a strong integration between metabolism
and inflammation. Because LXRs act as a cross-talk
between lipid metabolism and inflammation, they may
be beneficial in treating arthritis. The purpose of the pre-
sent study is to investigate the prophylactic and
disease-modifying effect of LXRs in a murine CIA, a
model that mimics human RA clinically and histologically.
We investigated whether a synthetic LXR agonist,
GW3965, could prevent the evolution of murine CIA and
suppress bone and cartilage destruction in CIA mice.
Materials and methods
CIA induction and treatment
All animals were housed according to the Animal Care
Committee of Yonsei University College of Medicine
guidelines. All experimental protocols were reviewed and
approved by the Animal Care Committee. Male DBA/1J
mice at 8–10 weeks of age (SLC, Shizoka, Japan) were
used for CIA induction. Bovine type II collagen (CII;
Sigma Chemical, St Louis, MO, USA) was dissolved in
0.01 M acetic acid at 2 mg/ml by stirring overnight at 4C.
Freund’s complete adjuvant was prepared by adding
Mycobacterium tuberculosis H37 RA (Difco, Detroit, MI,
USA) at 5 mg/ml. Mice were injected intradermally at the
base of the tail with 100 ml of emulsion (containing 100 g of
CII) on Days 1 and 21 as described previously [25]. All mice
were fed with GW3965, a synthetic LXR agonist, or vehicle,
beginning from Day 1 to Day 40. The synthetic LXR agonist,
GW3965, was provided by Jon L. Collins (GlaxoSmithKline
R&D, USA) and GW3965 treatment was performed in a
manner similar to that in the previous studies [26, 27].
Briefly, mice were fed a western diet (Research diets,
Central Lab. Animal Inc., Seoul, Korea; 21% fat, 1.5% cho-
lesterol) supplemented with GW3965 at a dose of 0.1, 0.3
and 1.0 mg/kg/day or vehicle control (0.5% methylcellu-
lose, 2% Tween-80) from Day 1 to Day 40.
Sham-treated mice were treated on Days 1 and 21 with
100 ml of 0.01 M acetic acid. Sham-treated mice were also
fed with GW3965 or vehicle (10% DMSO) from Day 1 to
Day 40. Ten mice were assigned to each group.
Clinical and histological assessment of CIA
An investigator blinded to the treatment regimen per-
formed all clinical examinations as previously described
[28], using the following system: Grade 0, no swelling;
Grade 1, slight swelling and erythema; Grade 2, moderate
swelling and oedema; Grade 3, extreme swelling and
pronounced oedema; and Grade 4, joint rigidity. Mice
were evaluated for arthritis on a daily basis. Each limb
was graded and limb scores added, giving a maximum
possible score of 16 per animal. For histological analysis,
mice were anaesthetized and sacrificed 40 days after pri-
mary immunization. Paws were randomly collected and
fixed in 4% buffered formaldehyde, decalcified, paraffin-
embedded, sectioned and stained with haematoxylin and
eosin (H&E). Histopathological changes were scored in a
blinded manner based on cell infiltration, cartilage
destruction and bone erosion parameters, as previously
described [29]. Minor differences between observers were
resolved by mutual agreement.
Immunohistochemical localization of inflammatory
mediators
Mice were anaesthetized and sacrificed on Day 40, and
paws and knee joints were removed for histopathological
examination, which was performed after fixation, decalci-
fication and paraffin embedding of tissue sections. Tissue
sections were prepared and stained with H&E.
Sections were sequentially incubated with specific anti-
bodies directed against murine TNF-a, IL-1b, iNOS or
COX-2 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) followed by the appropriate secondary antibodies
(ISU Abxis, Seoul, Korea). All tissue samples were coun-
terstained with haematoxylin. After immunohistochemical
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staining, expression of different markers in the joint syno-
vial tissue was scored semi-quantitatively on a four-point
scale, independently and blindly by two investigators, and
the averages were calculated. A score of 0 represented
minimal expression, 1 represented mild expression, 2 rep-
resented moderated expression, whereas 3 represented
abundant marker expression [30].
Measurement of pro-inflammatory cytokine levels
The TNF-a, IL-1b and IL-6 levels in serum from CIA mice
were determined by specific ELISA (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s
protocol. Both intra- and interassay coefficients of varia-
tion were <8% for all assays.
Assessments for GW3965 toxicity
We used 15 CIA mice for investigation of the toxicity of
GW3965: controls and CIA mice treated with 0.3 and
1.0 mg/kg of GW3965. We obtained blood from the
controls and the mice treated with GW3965 (0.3 and
1.0 mg/kg) after sacrifice, and examined white blood cell
count, haemoglobin, platelet count and levels of aspartate
aminotransferase, alanine aminotransferase, blood urea
nitrogen and creatinine for liver and kidney toxicity.
Statistics
The results are shown as the mean (S.E.M.). In experiments
involving histology or immunohistochemistry, the results
are representative of at least three experiments performed
on different days. Data were examined by one-way ana-
lysis of variance followed by a Bonferroni post hoc test for
multiple comparisons. A Mann–Whitney U-test was used
to compare the arthritis index medians. P< 0.05 was con-
sidered significant.
Results
Effect of GW3965 treatment on CIA evolution
CIA developed rapidly in mice immunized with CII. Clinical
signs of the disease, including periarticular erythema and
oedema, first appeared in the hind paws between 23 and
24 days after CII immunization, with a 100% CIA inci-
dence by Day 32 (Fig. 1A). Erythema and swelling in the
hind paws increased in frequency and severity in a
FIG. 1 Effects of GW3965 on arthritis onset and severity in CIA mice.
(A) The percentage of arthritic mice (arthritis scores >1) is significantly different between vehicle and GW3965 treatment.
Treatment with 0.1 mg/kg/day GW3965 slightly suppressed arthritis onset, whereas 0.3 and 1.0 mg/kg/day GW3965
significantly reduced arthritis incidence. (B) Median arthritis scores also indicate a significant difference between vehicle
and GW3965 treatment. Doses of 0.3 and 1.0 mg/kg/day of GW3965 significantly reduced arthritis incidence *P< 0.05.
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time-dependent manner, reaching maximum arthritis
indices between 32 and 34 days after CII immunization
in the vehicle-treated mice (Fig. 1B). GW3965 treat-
ment suppressed the evolution of CIA in a dose-
dependent manner, demonstrated by lower incidence
and reduced arthritis severity as shown in Fig. 1.
A 0.1 mg/kg/day dose of GW3965 also decreased arthritis
severity significantly, but did not remarkably suppress
arthritis onset, compared with 0.3 and 1.0 mg/kg/day
doses. There was no macroscopic evidence of either
hind paw erythema or oedema in the sham-treated mice
(data not shown).
On Day 40, histological evaluation of paws from CII-
immunized mice revealed signs of severe arthritis and
bone erosion. A comparison of the histological damage
scores is presented in Fig. 2. GW3965 treatment reduced
inflammatory cell infiltration and bone destruction in
CIA mice (Fig. 2A). A 0.3 and 1.0 mg/kg/day GW3965
treatment significantly reduced the histological damage
scores in the joint sections, compared with vehicle-
treated mice. However, no significant reduction in
arthritis was observed in the mice treated with 0.1 mg/kg
of GW3965. There was no evidence of disease
in the sham-treated mice from either treatment group
(Fig. 2B).
Effect of GW3965 treatment on TNF-a, IL-1b, iNOS and
COX-2 production
Figure 3 shows results from immunohistochemical
analysis of joint sections representative of at least two
experiments performed on different days. Joints
obtained from vehicle-treated mice showed positive
staining for TNF-a, IL-1b, iNOS and COX-2, localized
primarily to inflamed cells around the joints. GW3965-
treated mice with CIA showed significantly reduced
staining (Fig. 3A). Semi-quantitative analysis demon-
strated a significant dose-dependent decrease in TNF-a,
IL-1b, iNOS and COX-2 stain positivity in GW3965-
treated mice, compared with vehicle-treated mice.
There was no TNF-a, IL-1b, iNOS or COX-2 staining
around joints obtained from sham-treated mice
(Fig. 3B).
Effect of GW3965 treatment on pro-inflammatory
cytokine levels
The pro-inflammatory cytokine expression pattern,
as assessed by ELISA, is shown in Fig. 4. Compared
with vehicle-treated mice, GW3965-treated mice
had lower serum TNF-a, IL-1b and IL-6 levels. Serum
TNF-a levels in vehicle-treated and 0.1 mg/kg/day
GW3964-treated mice were not significantly different,
FIG. 2 Effects of GW3965 on histological changes.
(A) Joint sections from paws of vehicle-treated mice show inflammatory cell infiltration and bone erosion, but remarkably
reduced inflammatory cell infiltration in GW3965-treated mice (original magnification 100). (B) Treatment with 0.3 and
1.0 mg/kg/day of GW3965 significantly reduced the histological damage scores in CIA mice. Values are mean (S.E.M.) of
10 mice per group. *P< 0.01 vs sham-treated control; **P< 0.01 vs vehicle-treated CIA mice.
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but they were significantly greater than in 0.3 and
1.0 mg/kg/day GW3965-treated mice. IL-1b and IL-6
serum levels in vehicle-treated mice were significantly
higher than those in all GW3965-treated mice, but the
differences between GW3965 doses were not statistically
significant. There were no significant increases in
serum levels of any of the three cytokines in sham-treated
mice.
FIG. 3 Effects of GW3965 treatment on immunohistochemical staining for TNF-a, IL-1b, iNOS and COX-2.
(A) Vehicle-treated mice showed positive staining for TNF-a, IL-1b, iNOS and COX-2, which was localized primarily
to inflamed cells around the joints. Staining was significantly reduced in GW3965-treated CIA mice. There was no
specific staining in joints from sham-treated mice (original magnification 100). (B) Treatment with 0.3 and 1.0 mg/kg/day
of GW3965 significantly reduced TNF-a, IL-1b, iNOS and COX-2 expression. *P< 0.01 vs sham-treated control;
**P< 0.01 vs vehicle-treated mice with CIA.
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Toxicity of GW3965 in CIA mice
Table 1 shows the results of laboratory tests performed to
investigate the toxicity of GW3965. There were no differ-
ences in white blood cell counts, haemoglobin levels and
platelet counts between the controls and the mice treated
with GW3965 (0.3 and 1.0 mg/kg). Liver and kidney toxi-
cities were not observed in the mice treated with 0.3 and
1.0 mg/kg of GW3965.
Discussion
The present study investigated the potential usefulness of
a synthetic LXR agonist, GW3965, as an anti-inflammatory
agent to suppress arthritis in CIA mice, and found that
GW3965 suppresses CIA incidence and severity. Higher
GW3965 doses (0.3–1.0 mg/kg/day) reduced CIA inci-
dence up to 50% compared with vehicle-treated mice.
Although a 0.1 mg/kg/day GW3965 treatment also signifi-
cantly decreased CIA incidence, the effect was observed
at a relatively late time point, and disappeared with time in
comparison with higher GW3965 doses. In addition
to suppressing CIA onset, GW3965 treatment significantly
reduced CIA severity. GW3965 treatment signifi-
cantly reduced the median arthritis indices and histologi-
cal joint damage, compared with vehicle-treated mice.
Both effects were more prominent at higher GW3965
doses.
The regulatory action of LXRs in inflammatory
responses is well understood. In addition to the originally
identified atheroprotective effects [31, 32], LXRs have
recently been identified as macrophage inflammatory
pathway regulators. Synthetic LXR agonists, such as
GW3965 and T0901317, antagonise the expression of
pro-inflammatrory genes, such as iNOS, COX2, IL-6,
IL-1b, monocyte chemoattractant protein-1 (MCP-1),
MCP-3 and MMP9 [17–19]. The precise mechanisms by
which LXRs exert these anti-inflammatory effects remain
to be established, but a body of evidence implicates
inhibition of the NF-kB pathway. Cytokine or bacterial
component recognition by the corresponding receptor
initiates pro-inflammatory gene expression, and toll-
like receptor 3/4 activation by these signals blocks
LXR-dependent gene transcription. Moreover, ligand
activation of LXR inhibits inflammatory responses to cyto-
kines via a blockade of NF-kB signalling [15, 17, 19, 33].
In the rheumatoid synovium, activation of the NF-kB
pathway induces various genes that contribute to the
inflammatory response, such as TNF-a, IL-1b, COX-2,
MMPs and chemokines that recruit immune cells to the
inflamed pannus [34–36]. The present study demonstrated
that GW3865 treatment significantly reduced TNF-a, IL-1b,
iNOS and COX-2 expression in the joint tissue and serum
pro-inflammatory cytokine levels in CIA mice. Thus, the
suppressed CIA incidence and severity by GW3965 treat-
ment might result, at least in part, from NF-kB pathway
inhibition. Furthermore, GW3965 may serve as a negative
regulator of articular inflammation in CIA mice.
LXR-a is highly expressed in liver, adipose tissue and
macrophages, whereas LXR-b is expressed ubiquitously.
Recently, Chintalacharuvu et al. [37] showed both LXR-a
and LXR-b overexpression in synovium from RA patients,
but not in normal synovium. Although the therapeutic
effect of LXR agonists in established arthritis has not
been reported in the literature, the recent work
by Chintalacharuvu et al. [37] documented the regulatory
effect of a synthetic LXR agonist, T0901317, on
pro-inflammatory cytokine production and resultant joint
damage in lipopolysaccharide-treated mice [37]. These
results support the proposal that LXR agonists might
FIG. 4 Effects of GW3965 treatment on pro-inflammatory
cytokine production.
GW3965 treatment significantly reduced TNF-a (A), IL-1b
(B) and IL-6 (C) serum levels in CIA mice compared with
vehicle-treated mice. *P< 0.01 vs sham-treated control;
**P< 0.01 vs vehicle-treated mice with CIA. ND: not
detected.
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prove clinically useful in suppressing autoimmune
diseases, in particular RA. The present study used CIA
mice, which has proved to be a useful RA model,
since it possesses many cellular and humoral immunity
characteristics found in human RA [38, 39]. Similar to
previous observations, GW3865 treatment, in the present
study, significantly reduced the degree of joint damage in
CIA mice by decreasing the expression of inflammatory
mediators in a dose-dependent manner. The most inter-
esting finding was that higher LXR agonist doses
significantly suppress the evolution of arthritis in
CIA mice, which indicates a prophylactic effect of LXR
agonist against arthritis onset.
Although the function of LXRs to induce macrophage
cholesterol efflux and inhibit inflammatory gene expres-
sion could generate widespread interest in these proteins
as potential targets for atherosclerosis and autoimmune
disease treatment, synthetic LXR agonists can increase
triglyceride levels. LXR-a is the predominant LXR
expressed in liver, and the ability of LXR agonists to stim-
ulate hepatic lipogenesis likely results primarily from
LXR-a activation [40–42]. In this regard, the present
study has some potential limitations: (i) we evaluated the
prophylactic effect of a non-selective, not
isotype-selective, synthetic LXR agonist on the evolution
of CIA in mice and (ii) we demonstrated only the prophy-
lactic action of GW3965 on the development of CIA and its
therapeutic effects on established disease was not eval-
uated. The demonstration of prophylactic effect alone
could not be sufficient for the clinical significance of LXR
agonist for the treatment of RA. Thus, the present study
mandates future investigations to define the roles
of tissue- or isotype-selective LXR agonists in the RA
inflammatory response and to investigate the thera-
peutic effect of synthetic LXR agonists on established
disease.
In conclusion, treatment with a synthetic LXR agonist
significantly suppressed arthritis incidence and attenuated
its severity in CIA mice. This LXR agonist reduced the
degree of joint damage by inhibiting the expression
of pro-inflammatory mediators. The data obtained in the
present study support the conclusion that LXR activation
exerts a beneficial effect in RA, given its anti-inflammatory
properties, and could serve as a novel prophylactic mod-
ality for RA.
Rheumatology key messages
. GW3965 prophylaxis significantly reduced arthritis
incidence and attenuated the clinical and histologi-
cal severity in CIA mice.
. GW3965 prophylaxis significantly reduced inflam-
matory mediator production in joint sections and
serum pro-inflammatory cytokine levels in a
dose-dependent manner.
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